 Concert Pharmaceuticals NASDAQ:CNCE was upgraded by investment analysts at BidaskClub from a hold rating to a buy rating in a research note issued on Tuesday, BidAskClub reports. CNCE has been the topic of a number of other research reports. Zacks Investment Research lowered Concert Pharmaceuticals from a buy rating to a hold rating in a ... 